Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside

American Society of Clinical Oncology Educational Book
Aurore PerrotHervé Avet-Loiseau

Abstract

In the past 15 years, significant improvements in overall survival have been observed in multiple myeloma (MM), mainly due to the availability of novel drugs with variable mechanisms of action. However, these improvements do not benefit all patients, and some of them, defined as high risk, still display short survival. The most important risk factors are the genetic abnormalities present in the malignant plasma cells. The most important high-risk features are the del(17p), the del(1p32), the t(4;14), and 1q gains. Assessing these markers is mandatory at diagnosis and at least at first relapse, since it has been clearly shown that the lenalidomide-dexamethasone combination is not efficient in these high-risk patients. In contrast, a triplet combination adding a proteasome inhibitor or a monoclonal antibody to the lenalidomide-dexamethasone backbone clearly improves the survival. Another way to improve the outcome would be to specifically target genetic abnormalities with specific inhibitors. The sequencing of more than 1,000 MM exomes revealed again a huge heterogeneity. The most frequent mutations involve the KRAS and NRAS genes (20%-25% each). However, to date, no good RAS-inhibitors are clinically available, preventing target...Continue Reading

References

Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Jul 17, 2010·Haematologica·Laurence LodéHervé Avet-Loiseau
Jul 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hervé Avet-LoiseauJean-Luc Harousseau
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson
Mar 25, 2011·Nature·Michael A ChapmanTodd R Golub
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hervé Avet-LoiseauPhilippe Moreau
Jan 16, 2013·Cell Reports·Ludmil B AlexandrovMichael R Stratton
Mar 16, 2013·Hematological Oncology·Anna YordanovaIngo G H Schmidt-Wolf
Apr 25, 2013·Cancer Discovery·Mindaugas AndrulisMarc S Raab
Jan 17, 2014·Nature Communications·Niccolo BolliNikhil C Munshi
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Aug 1, 2015·Leukemia·C J HeuckG Morgan
Aug 5, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboPhilippe Moreau
Aug 19, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian A WalkerGareth J Morgan
Oct 31, 2015·Blood·Marie-Lorraine ChretienHervé Avet-Loiseau
Apr 28, 2016·The New England Journal of Medicine·Philippe MoreauUNKNOWN TOURMALINE-MM1 Study Group
Aug 25, 2016·The New England Journal of Medicine·Antonio PalumboUNKNOWN CASTOR Investigators
Oct 6, 2016·The New England Journal of Medicine·Meletios A DimopoulosUNKNOWN POLLUX Investigators

❮ Previous
Next ❯

Citations

Jul 25, 2019·American Journal of Hematology·Irit AviviArtur Jurczyszyn
Jul 21, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mehmet Kemal SamurNikhil C Munshi
May 28, 2019·Current Oncology Reports·Crystal Antoine-Pepeljugoski, Marc Justin Braunstein
Jun 15, 2019·Acta Pharmacologica Sinica·Xue-Han ChenTie Zhang
Jul 25, 2020·Haematologica·Annamaria Gulla, Kenneth C Anderson
Dec 2, 2020·Cancers·Titouan CazaubielAurore Perrot
Oct 16, 2020·Haematologica·Annamaria Gulla, Kenneth C Anderson
Dec 24, 2020·Acta Clinica Belgica·Marie-Christiane VekemansNathalie Meuleman

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Related Papers

Nihon rinsho. Japanese journal of clinical medicine
Makoto Sasaki, Norio Komatsu
Nihon rinsho. Japanese journal of clinical medicine
Tadao Ishida
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Hervé Avet-LoiseauJean-Luc Harousseau
© 2022 Meta ULC. All rights reserved